Special Issue

Neuromodulation: From Theories to Therapies

Message from the Guest Editor

Neuromodulation is the alteration of neuronal and synaptic properties by neurons, neuronal substances, or via the targeted delivery of an electromagnetic or chemical stimulus, etc., to specific neurological sites in the body to normalize or modulate nervous tissue function. Neuromodulation, whether electrical or magnetic, at the brain- or at the spinal cord-level, employs the body's natural biological response by stimulating nerve cell activity that can influence populations of nerves by releasing transmitters or other chemical messengers that can modulate the excitability and firing patterns of neural circuits. The end effect is a "normalization" and/or "modulation" of neural network function from its perturbed state. Neuromodulation is an increasingly accepted treatment for neurological and psychiatric disorders, and its significance in the field of neurorehabilitation is growing and evolving.

Guest Editor

Dr. Hatice Kumru Institut Guttmann, Badalona, Spain

Deadline for manuscript submissions

closed (15 December 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/123341

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).